Personalis — Third Quarter 2026 Earnings Summary

Personalis, Inc. reported third-quarter 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the same period of 2025, driven by growth in clinical test volume and pharma services. The company delivered 13,157 clinical tests during the quarter, generating $4.4 million in clinical revenue, while core revenue streams including population sequencing and pharma testing services totaled $17.2 million. Financial results showed a net loss of $33.8 million for the quarter, with the company ending the period with approximately $190.6 million in cash and investments. Additionally, Personalis announced the launch of its NeXT Personal Real-Time Variant Tracker and reported positive interim data from its B-STRONGER-1 study on triple-negative breast cancer.